- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSVpreF MDV, RSVpreF SDV
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 453 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 6
- States / cities
- South Miami, Florida • Stockbridge, Georgia • Idaho Falls, Idaho + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 265
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV F vaccine with adjuvant, Formulation buffer
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 4,636 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Fort Defiance, Arizona + 43 more
- Conditions
- Congenital Heart Disease
- Interventions
- Motavizumab, Palivizumab
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- Up to 24 Months
- Enrollment
- 1,236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 30
- States / cities
- Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 25 more
- Conditions
- Healthy
- Interventions
- Motavizumab, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 0 Months to 6 Months
- Enrollment
- 2,127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2010
- U.S. locations
- 12
- States / cities
- Chinle, Arizona • Cibecue, Arizona • Fort Definace, Arizona + 9 more
- Conditions
- Respiratory Tract Infections
- Interventions
- Rilematovir, Rilematovir X mg/kg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 1 Day to 5 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Jackson, Mississippi • The Bronx, New York + 2 more
- Conditions
- Healthy Participants
- Interventions
- Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 1,142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 37
- States / cities
- Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more
- Conditions
- Respiratory Tract Infections, Influenza, Human, Respiratory Syncytial Virus Infections
- Interventions
- Not listed
- Lead sponsor
- Janssen Pharmaceutica N.V., Belgium
- Industry
- Eligibility
- Not listed
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Pensacola, Florida
- Conditions
- Respiratory Syncytial Virus, Human Metapneumovirus
- Interventions
- mRNA-1345, mRNA-1365, Placebo, Nimenrix
- Biological · Drug
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 5 Months to 24 Months
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Not listed
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 1 Month to 6 Months
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 50 more
- Conditions
- COVID-19 Respiratory Infection, Influenza A, Influenza Type B, RSV Infection
- Interventions
- Labcorp COVID-19+Flu+RSV Test Home Collection Kit
- Device
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 2 Years to 89 Years
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- lumicitabine, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 10
- States / cities
- Fresno, California • Orange, California • Stanford, California + 7 more
- Conditions
- Lower Respiratory Tract Illness
- Interventions
- RSVpreF, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 38,861 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 176
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 119 more
- Conditions
- RSV Immunisation
- Interventions
- RSVt Vaccine, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 21 Months
- Enrollment
- 6,300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Tucson, Arizona + 41 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID ΔM2-2 Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- Alhambra, California • La Jolla, California • Aurora, Colorado + 3 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- D46/NS2/N/ΔM2-2-HindIII, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A) middle dose formulation vaccine, RSV (GSK3389245A) high dose formulation vaccine, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 23 Months
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3, Placebo (Normal Saline)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 502 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Rochester, New York
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MAT vaccine, dTpa vaccine
- Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 9 Years to 49 Years · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Miami, Florida • Beaumont, Texas
- Conditions
- Respiratory Syncytial Virus Prevention
- Interventions
- Ad26.RSV.PreF-based Vaccine
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Athens, Alabama • Vestavia Hills, Alabama • Phoenix, Arizona + 8 more
- Conditions
- Respiratory Tract Infections
- Interventions
- Formulation A, Formulation B, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,235 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 40
- States / cities
- Mobile, Alabama • Anaheim, California • La Mesa, California + 30 more
- Conditions
- SARS-CoV-2, Influenza, RSV
- Interventions
- mRNA-1010, mRNA-1345, mRNA-1273.214, mRNA-1045, mRNA-1230
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 392 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 14
- States / cities
- DeLand, Florida • Hollywood, Florida • St. Petersburg, Florida + 11 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Placebo, MEDI8897 10 mg, MEDI8897 25 mg, MEDI8897 50 mg
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- Up to 12 Months
- Enrollment
- 151 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Anaheim, California • Ontario, California • Syracuse, New York + 4 more
- Conditions
- Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
- Interventions
- Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 777 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 19
- States / cities
- Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more
- Conditions
- RSV Infection
- Interventions
- Obeldesivir, Obeldesivir Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Guntersville, Alabama + 81 more